Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZOYxKSzVyPUCuOlEzOzdizszN MXLTRW5ITVJ?
H4 NXrzWos{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;tTWM2OD1yLk[2Nlgh|ryP MYnTRW5ITVJ?
PA-1 NXnY[IRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\QTWM2OD1yLki3NFk3KM7:TR?= M3jtOXNCVkeHUh?=
NKM-1 NXfIemdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\iS45KSzVyPUGuNFQ6OzFizszN MnXoV2FPT0WU
NEC8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwMkG1O|Ih|ryP M1f0eHNCVkeHUh?=
EoL-1-cell Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PZOGlEPTB;MT6yOlcxOSEQvF2= M3nxXXNCVkeHUh?=
K5 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3vTWM2OD1zLkSyNFczKM7:TR?= MYTTRW5ITVJ?
QIMR-WIL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTyVllCUUN3ME2xMlYxQDV2IN88US=> NEDpd|JUSU6JRWK=
MOLT-16 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPQTWM2OD1zLke4OlA1KM7:TR?= MULTRW5ITVJ?
CHP-212 M1[3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjnUZBGUUN3ME2xMlgyOzZ7IN88US=> MVPTRW5ITVJ?
CTB-1 NVXzWo1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP2O4pKUUN3ME2yMlAzOjR4IN88US=> MUPTRW5ITVJ?
MOLT-4 M2XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSz[pZKSzVyPUKuN|I5PTNizszN NHm0PWtUSU6JRWK=
A101D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXLTFFOUUN3ME2yMlM2ODFizszN M{\MV3NCVkeHUh?=
DOHH-2 NFP2[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfEXYVKSzVyPUKuOFIzPzlizszN MVPTRW5ITVJ?
ES4 NXjpd2tJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPHOllKSzVyPUKuOFMyPTVizszN M2nKSXNCVkeHUh?=
SW780 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u3fWlEPTB;Mj61NFg5OyEQvF2= M1;wTXNCVkeHUh?=
VA-ES-BJ NXfRfZZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M175e2lEPTB;Mj61OFEyKM7:TR?= NEDlZmpUSU6JRWK=
RPMI-8866 M4DBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwNU[yNVQh|ryP MYHTRW5ITVJ?
ML-2 NIDGXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OxVWlEPTB;Mj61OlU4PiEQvF2= M2PzPHNCVkeHUh?=
MSTO-211H M4i5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWix[o9OUUN3ME2yMlU4PDVzIN88US=> NWeyeoJCW0GQR1XS
JVM-3 M{DnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy5fpFKSzVyPUKuOVk{OjRizszN NXjMOpBTW0GQR1XS
A3-KAW NWD2VGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fxPWlEPTB;Mj62NVgyQCEQvF2= M3j6dHNCVkeHUh?=
DK-MG NX;nXIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfHUmZQUUN3ME2yMlYzPDdzIN88US=> Mm\uV2FPT0WU
LNCaP-Clone-FGC MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX3S5hKSzVyPUKuOlQ{OThizszN NVL5V5pCW0GQR1XS
HT-144 NFX4ZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;STWM2OD1{Lk[0OVc4KM7:TR?= NGTTZ3BUSU6JRWK=
NB69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln2TWM2OD1{Lk[1N|M1KM7:TR?= NHnCWpdUSU6JRWK=
A172 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJwNke1PFgh|ryP MnnZV2FPT0WU
RS4-11 NXvhVmxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrhWpI3UUN3ME2yMlczPDB5IN88US=> M4XuXXNCVkeHUh?=
DU-4475 NFjSbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJwN{m1NFIh|ryP MkL1V2FPT0WU
SJSA-1 NHLUTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3OXmQzUUN3ME2yMlgzPTV4IN88US=> NFO0OJdUSU6JRWK=
BV-173 NH;pWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJwOES0N|kh|ryP NIjiXJBUSU6JRWK=
U-2-OS NH3Zb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJwOUGwO{DPxE1? NYLlVZNZW0GQR1XS
CHP-134 NVXrc|RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTKTWM2OD1{LkmzPFgzKM7:TR?= M4XKdnNCVkeHUh?=
D-502MG NGS0e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPDd3hnUUN3ME2yMlk4OTV2IN88US=> NF\BUodUSU6JRWK=
KS-1 M1T6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNwMEG2NlMh|ryP M{HmWnNCVkeHUh?=
A204 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HTSWlEPTB;Mz6wOVU5QCEQvF2= NF\EVXBUSU6JRWK=
KGN NX3KNJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LCbmlEPTB;Mz6wPFQ6PiEQvF2= M{jINnNCVkeHUh?=
NCI-H292 NGfvWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPPTWM2OD1|LkGyNFI5KM7:TR?= MY\TRW5ITVJ?
CAKI-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPLTWM2OD1|LkGyOlk1KM7:TR?= MUjTRW5ITVJ?
C2BBe1 M{DVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjtbGhKSzVyPUOuNVcxOjZizszN NW\1flZkW0GQR1XS
NB10 NYrCNm1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTNwMkC5OlYh|ryP NXvNTZFnW0GQR1XS
MHH-NB-11 NXrBVlllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr6SphVUUN3ME2zMlI3QDJ5IN88US=> NUn5NnRlW0GQR1XS
NCI-SNU-1 NEfBNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDuNWlHUUN3ME2zMlI4QDR|IN88US=> MWHTRW5ITVJ?
HCT-116 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LFZmlEPTB;Mz6zNFM{PSEQvF2= M2rZUHNCVkeHUh?=
G-401 NUH1[Jl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fPWGlEPTB;Mz6zOlMzOiEQvF2= M17PTHNCVkeHUh?=
MN-60 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwNESwPVIh|ryP M1\HeXNCVkeHUh?=
SW982 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;YeGVKSzVyPUOuOVA5PDhizszN MljSV2FPT0WU
RKO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNwNUO5N|Yh|ryP MWXTRW5ITVJ?
D-283MED MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[y[2hKSzVyPUOuOVc6QDZizszN NI\Vb2hUSU6JRWK=
LB996-RCC M2jVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\5TWM2OD1|Lk[yOVU5KM7:TR?= MXrTRW5ITVJ?
A549 NYLFO|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNwNkO1OVIh|ryP MmDnV2FPT0WU
LB2241-RCC M2PWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrlNGVKSzVyPUOuOlU4ODhizszN MVLTRW5ITVJ?
SK-HEP-1 M4fPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ETWM2OD1|Lke0Nlk4KM7:TR?= MUnTRW5ITVJ?
G-402 NWrETndpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwOEC4N|Ih|ryP MoH1V2FPT0WU
GOTO Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fRfmlEPTB;Mz64OFM{OyEQvF2= NEHybY1USU6JRWK=
LOXIMVI NV3QPI5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDiV3ZbUUN3ME2zMlg2Pjd3IN88US=> MlXLV2FPT0WU
NH-12 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLKTWM2OD12LkCxPVU6KM7:TR?= NXPOc5BWW0GQR1XS
CTV-1 NUXoZmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XGSmlEPTB;ND6wO|k4OyEQvF2= NYDXb5dLW0GQR1XS
CP50-MEL-B M1y0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ewZ2lEPTB;ND6yOFM6OiEQvF2= MnnLV2FPT0WU
RH-18 M2q4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTRwMke3NFYh|ryP M{nkfnNCVkeHUh?=
NB17 NXrvV3lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRwM{G3Olgh|ryP NFjsN2pUSU6JRWK=
A375 NWfaS2loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzGTWM2OD12LkOzOVI1KM7:TR?= M3m2[nNCVkeHUh?=
IST-MES1 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LNOGlEPTB;ND60NVQyOSEQvF2= NEX4SllUSU6JRWK=
MZ2-MEL MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfTR25KSzVyPUSuOVAyPTVizszN NXjpXpR6W0GQR1XS
CAL-54 NUXyTmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrDfmxxUUN3ME20MlU{ODF7IN88US=> NX3xZpBZW0GQR1XS
NCI-H28 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzkTolKSzVyPUSuOlI4OTdizszN M3;uNnNCVkeHUh?=
D-247MG NWrHT202T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli4TWM2OD12Lke1NFczKM7:TR?= MV7TRW5ITVJ?
NCI-H460 NXe0W|BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwOUGxNlch|ryP MYnTRW5ITVJ?
MCF7 NETKb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD13LkS0NlQ1KM7:TR?= NIGxOHhUSU6JRWK=
697 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrnXpU4UUN3ME21MlQ1PTVizszN MXzTRW5ITVJ?
ONS-76 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG3TWM2OD13LkW3NFA6KM7:TR?= NVO5TlZWW0GQR1XS
C32 NXn0ZoxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfaSINKSzVyPUWuOlAxOjlizszN MYjTRW5ITVJ?
OS-RC-2 NHrrbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG1ZW05UUN3ME21Mlc{QDh5IN88US=> MVLTRW5ITVJ?
MEL-HO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13G[mlEPTB;NT64OVY3PyEQvF2= MmnYV2FPT0WU
LoVo MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\CSmlEPTB;Nj6wNVYzPCEQvF2= MXXTRW5ITVJ?
AGS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPZTWM2OD14LkG0PFI5KM7:TR?= NX7Bc404W0GQR1XS
GI-ME-N MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZwMkK0NlEh|ryP NHjmbZZUSU6JRWK=
H-EMC-SS NG\wNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7SRYxKSzVyPU[uN|g3KM7:TR?= NVPicYJCW0GQR1XS
RVH-421 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTZwNEK0Nlgh|ryP MX7TRW5ITVJ?
SW954 M4LUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SycGlEPTB;Nj61OVU4OiEQvF2= NIOzUWNUSU6JRWK=
NB5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TKT2lEPTB;Nj61OlE5OyEQvF2= NFPrPWRUSU6JRWK=
NCI-H2122 M122ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrOb4lmUUN3ME22MlU5Pzl|IN88US=> NX;PTGpCW0GQR1XS
AM-38 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TCV2lEPTB;Nj63OVY{QSEQvF2= NHXYU49USU6JRWK=
KNS-81-FD NYW0O4g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzwT2xKSzVyPU[uO|Y1QTRizszN NW\QfFB[W0GQR1XS
LS-513 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\NdodKSzVyPU[uO|kxOjZizszN MWfTRW5ITVJ?
A427 NFG2fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwOEe4Nlkh|ryP M2\ic3NCVkeHUh?=
WM-115 M3q4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZwOUOyN{DPxE1? M1\kN3NCVkeHUh?=
COLO-829 NGn1SWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHMTWM2OD15LkK0NVg5KM7:TR?= NX\QVIF1W0GQR1XS
NCI-H1650 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTdwM{myNlgh|ryP M2OzTHNCVkeHUh?=
NCI-H358 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr5cW5tUUN3ME23MlQ1QDd7IN88US=> Mnf4V2FPT0WU
HT-1080 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnOV4FPUUN3ME23MlQ5OjV2IN88US=> MXfTRW5ITVJ?
HCC2218 M3ztN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXuc2VKSzVyPUeuOlI6PyEQvF2= MUfTRW5ITVJ?
NCI-H661 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfCeIlKSzVyPUeuPFcxPjlizszN NGjhUGtUSU6JRWK=
KM-H2 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13XS2lEPTB;Nz64PFY6PCEQvF2= MVfTRW5ITVJ?
RPMI-2650 M3vKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILIbWVKSzVyPUeuPVQ1OTRizszN MmfPV2FPT0WU
NCI-H226 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH35WZRKSzVyPUiuNlEyOjJizszN NFHsO2RUSU6JRWK=
MKN45 NWHzV2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G0TWlEPTB;OD6yOlYxOiEQvF2= M3ixXXNCVkeHUh?=
D-392MG NHO5UYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XwTGlEPTB;OD61NlczOiEQvF2= MX\TRW5ITVJ?
RCC10RGB NVzLN2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jH[2lEPTB;OD64OlY6PSEQvF2= MofSV2FPT0WU
CAL-51 NYrX[4NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf6TnhzUUN3ME25MlExOjVzIN88US=> NUjEeJNrW0GQR1XS
COLO-678 NV3uR4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\wTWM2OD17LkOyPFEyKM7:TR?= NGDhXVJUSU6JRWK=
SK-MEL-24 M{LOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnoRWpKSzVyPUmuOVU5PTZizszN NUH6[oFRW0GQR1XS
SK-MEL-30 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTNTWM2OD17Lkm0OFc3KM7:TR?= NUH5WnRtW0GQR1XS
MMAC-SF NIW0XnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jwOGlEPTB;MUCuN|k3OSEQvF2= NEXrPHhUSU6JRWK=
NTERA-S-cl-D1 NHLJWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzvdZJJUUN3ME2xNE43PTB6IN88US=> MVrTRW5ITVJ?
NB12 NUPF[pE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6zTWM2OD1zMT61NFMh|ryP MknsV2FPT0WU
UACC-257 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFzLki2PVUh|ryP NXXLc5U3W0GQR1XS
LAN-6 M{G3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFzLkm5Nlgh|ryP MoK3V2FPT0WU
SW1573 NHjCTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjXXnJSUUN3ME2xNk4{ODh4IN88US=> M2nQNXNCVkeHUh?=
NMC-G1 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\UXFBKSzVyPUGyMlQyPzVizszN NWrxcmNkW0GQR1XS
SHP-77 NFnYSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXxXZpKSzVyPUGyMlU2PzRizszN Ml7wV2FPT0WU
IGROV-1 M2foVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjkUnJKSzVyPUGyMlY2PzNizszN NUDxbVM{W0GQR1XS
22RV1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PmVWlEPTB;MUKuPFA2QSEQvF2= M2[3U3NCVkeHUh?=
SK-MEL-3 NHjnU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWyZYFzUUN3ME2xN{4{QTd|IN88US=> M2PDNnNCVkeHUh?=
NCI-H1563 NEHZUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\B[GpKSzVyPUGzMlQzODJizszN M2HKb3NCVkeHUh?=
IGR-1 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\6XWlEPTB;MUSuNFM1PyEQvF2= M1HZUHNCVkeHUh?=
EW-3 NX7xTpJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XvcWlEPTB;MUSuNVY{QSEQvF2= M{HlSnNCVkeHUh?=
JEG-3 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITLNpdKSzVyPUG0MlQ6PTNizszN NYnMeVlzW0GQR1XS
ES3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzQO5dQUUN3ME2xOE43PTZ{IN88US=> M3Xod3NCVkeHUh?=
MDA-MB-175-VII M1rzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPxRphIUUN3ME2xOE44OTFzIN88US=> MXfTRW5ITVJ?
P30-OHK MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS0WZFKSzVyPUG1MlA1QTZizszN MnTJV2FPT0WU
GP5d MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwTWM2OD1zNT6xOFY3KM7:TR?= MXTTRW5ITVJ?
HMV-II NIP6d4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX6U3BKSzVyPUG1MlM{OzNizszN MV;TRW5ITVJ?
COLO-679 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr6TWM2OD1zNT61NFEh|ryP NYPUeFZXW0GQR1XS
JAR M{nqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[xTI1KSzVyPUG1MlczODVizszN M2[5U3NCVkeHUh?=
NCI-H1666 NEKydWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HQd2lEPTB;MUWuPVM6QSEQvF2= MmXWV2FPT0WU
SW48 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF3Lkm1NVYh|ryP MYrTRW5ITVJ?
NCI-H720 NGLESVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS0VW1KSzVyPUG1Mlk6QDlizszN M3fHUnNCVkeHUh?=
HT-1197 NI\ZdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m2PWlEPTB;MU[uNFM2OiEQvF2= Ml\pV2FPT0WU
HL-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF4LkCzPFQh|ryP M1\kW3NCVkeHUh?=
BEN MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17xbWlEPTB;MU[uOVY{QCEQvF2= NGfyfJZUSU6JRWK=
HAL-01 NYLNPI5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfhXWJKSzVyPUG2Mlg6ODlizszN M3PlcXNCVkeHUh?=
SW900 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2wfYVYUUN3ME2xOk46OTN{IN88US=> NHP3VGhUSU6JRWK=
SBC-1 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDBTWM2OD1zNz61OFI6KM7:TR?= Mnv6V2FPT0WU
SH-4 NVfN[nVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonoTWM2OD1zNz61PFQyKM7:TR?= NYPWS5p7W0GQR1XS
UACC-62 NVLKS3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;GXWlEPTB;MUeuO|Y{PyEQvF2= NUjqRmJFW0GQR1XS
BHT-101 M2HpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzxTWM2OD1zOT64O|A2KM7:TR?= M3vJ[HNCVkeHUh?=
DB NYXudG9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTGeXRVUUN3ME2yNU42PjR7IN88US=> NXuySlF[W0GQR1XS
SK-MEL-1 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nKXWlEPTB;MkGuOVg4OiEQvF2= MmjLV2FPT0WU
NCI-H747 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ{LkezO|kh|ryP NHTJZnRUSU6JRWK=
SK-LU-1 NXHmO5ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ|LkO1NlQh|ryP NHn5TIJUSU6JRWK=
KG-1 NETHc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjudmtKSzVyPUKzMlQ6PDZizszN M{nTdnNCVkeHUh?=
LXF-289 M3fNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHDTWM2OD1{Mz63NVQh|ryP NYTuWYN1W0GQR1XS
HCC1954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDTTWM2OD1{ND64PFQ1KM7:TR?= NGr5NpNUSU6JRWK=
Ramos-2G6-4C10 NVyyT5NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ4LkS5PFEh|ryP MYLTRW5ITVJ?
DBTRG-05MG NGW1cnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICzOGJKSzVyPUK2MlY1QDhizszN Mmr4V2FPT0WU
NCI-H2052 NELXTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ5LkW2PFQh|ryP MXvTRW5ITVJ?
RMG-I M3\4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTmdFVjUUN3ME2yPU41OTN7IN88US=> NFf6Z2dUSU6JRWK=
H9 NIfIRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXJVGZsUUN3ME2zNU4{ODB6IN88US=> Mm\1V2FPT0WU
GR-ST NYnDW2M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN{LkS0OVMh|ryP M4\VWHNCVkeHUh?=
Mo-T NYTHenhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN{LkWwOFYh|ryP NIrtZo1USU6JRWK=
SW1088 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDTe4lKSzVyPUOyMlk5ODFizszN M1\qUnNCVkeHUh?=
LB2518-MEL MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPEUm86UUN3ME2zN{4xPzl5IN88US=> MljSV2FPT0WU
NCI-H82 NGTpPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj2bXlKSzVyPUOzMlE3PjFizszN M4THUXNCVkeHUh?=
LAMA-84 NYC2[YNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmwTWM2OD1|ND62NFc{KM7:TR?= NIX0TZdUSU6JRWK=
KYSE-450 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P0VWlEPTB;M{SuOlc4PiEQvF2= NH\BS5lUSU6JRWK=
LU-99A NVH2T5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHZbFB4UUN3ME2zOU4xODB5IN88US=> MVTTRW5ITVJ?
BE-13 NFH0fHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDVcXhKUUN3ME2zOU43PTR3IN88US=> Mo\SV2FPT0WU
GAK M4nJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD4TWM2OD1|NT62PVUh|ryP NWS1NnRxW0GQR1XS
NCI-H1573 NVTxeo1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnETWM2OD1|NT64PFE5KM7:TR?= NY\YcZRGW0GQR1XS
AsPC-1 MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTN4LkG1Nlch|ryP NXLTd5BXW0GQR1XS
HDLM-2 NYj3OHJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTN4LkOxOkDPxE1? MX\TRW5ITVJ?
NCI-H441 M{PWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfKTWM2OD1|Nz6wOlkyKM7:TR?= M{PodXNCVkeHUh?=
CAL-27 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKwdnBKSzVyPUO3MlczOzFizszN M1vvfXNCVkeHUh?=
OVCAR-3 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnzT2FEUUN3ME2zPU4{OThzIN88US=> MojaV2FPT0WU
RPMI-8226 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrHOJFKSzVyPUO5MlU6QCEQvF2= NEHyXHBUSU6JRWK=
EFO-21 NGrF[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRyLkW4NVQh|ryP NH3IN2ZUSU6JRWK=
SNU-C2B MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTtTWM2OD12MT61NFg1KM7:TR?= NUXlbHBZW0GQR1XS
VM-CUB-1 M1vJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:5U4hKSzVyPUSzMlgxOzdizszN M3PFd3NCVkeHUh?=
NCI-H2087 M2ezOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHOOIFKSzVyPUS1MlAzOzNizszN MWPTRW5ITVJ?
EW-16 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULKeIh1UUN3ME20Ok4{OTN5IN88US=> NUDZdYZJW0GQR1XS
SK-N-AS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXpTWM2OD12Nj63NVY4KM7:TR?= NGDmXHlUSU6JRWK=
COR-L105 M4HuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD12Nj64PFU4KM7:TR?= NWK2PIZEW0GQR1XS
DEL M4f1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmzcpl7UUN3ME20PE4xPDJ7IN88US=> MX\TRW5ITVJ?
JVM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lyd2lEPTB;NEiuNFU2QCEQvF2= NWLSNFhFW0GQR1XS
KARPAS-45 MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR7LkS1N|gh|ryP MXXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID